Results 241 to 250 of about 1,444,670 (278)
Some of the next articles are maybe not open access.
First-in-class cardiac myosin inhibitor reduces symptoms of HCM
Nature Reviews Cardiology, 2020Mavacamten, a first-in-class cardiac myosin inhibitor, reduces symptoms and improves health status in patients with obstructive hypertrophic cardiomyopathy, according to findings from the EXPLORER-HCM trial.
openaire +2 more sources
Advances in Cardiovascular Pharmacotherapy. I. Cardiac Myosin Inhibitors
Journal of Cardiothoracic and Vascular AnesthesiaHypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy. The disease is characterized by asymmetric left ventricular (LV) remodeling with myocyte disarray and interstitial fibrosis, a hypercontractile state, dynamic subaortic obstruction of the LV outflow tract, impaired LV diastolic function, atrial and ventricular arrhythmias ...
Paul S, Pagel +3 more
openaire +2 more sources
The Revolution of Cardiac Myosin Inhibitors in Patients With Hypertrophic Cardiomyopathy
Canadian Journal of CardiologyHypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy worldwide and causes significant morbidity and mortality. For decades, medical treatment options have been limited and untargeted, with frequent need for invasive interventions not readily accessible to many HCM patients.
Rebecca Haraf, Hany Habib, Ahmad Masri
openaire +2 more sources
Drug Design, Development and TherapyHypertrophic cardiomyopathy (HCM) is a common inherited disease with substantial residual morbidity despite established pharmacological and surgical therapies. We conducted a narrative review of the current evidence on cardiac myosin inhibitors, drawing on published studies up to July 2025, including pivotal clinical trials, real-world cohorts, and ...
Hou,Lianglei +3 more
exaly +4 more sources
Two cardiac myosin inhibitors in the treatment of obstructive hypertrophic cardiomyopathy
MedA key area of therapeutic progress in obstructive hypertrophic cardiomyopathy revolves around the emergence of cardiac myosin inhibitors, of which mavacamten and aficamten represent the first and second molecules. We summarize the key research evidence, including many similarities and potential differences between various clinical trials studying these
Milind Y, Desai, Eugene, Braunwald
openaire +2 more sources
Discovery of a novel cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy
Chinese Chemical LettersLihong Hu, An Pan
exaly +2 more sources
Heart of the matter: A GP’s guide to cardiac myosin inhibitors
InnovAiT: Education and inspiration for general practiceHypertrophic obstructive cardiomyopathy (HOCM) is a heritable heart condition. It causes hypertrophy of the heart muscle and left ventricular outflow tract obstruction. Hypertrophic cardiomyopathy (HCM) is one of the most prevalent inherited cardiac disorders, with more than 1400 mutations discovered.
Tamara Naneishvili +8 more
openaire +3 more sources
Recent trend in the therapy of hypertrophic cardiomyopathy: Cardiac myosin inhibitors
2023Cardiac myosin inhibitors are a new class of drugs that have recently been approved in obstructive hypertrophic cardiomyopathy. The main mechanism of action is to reduce the pathologically increased cardiac hypercontractility. Current drug therapies have not been demonstrated to modify the natural progress of the disease.
DEMİRKIRAN, Cahit +2 more
openaire +1 more source
FDA approves first cardiac myosin inhibitor
Nature Reviews Drug Discovery, 2022openaire +1 more source
Cardiac Myosin Inhibitors for Managing Obstructive Hypertrophic Cardiomyopathy
JACC: Heart Failure, 2023John W. Ostrominski +3 more
openaire +1 more source